BMS, Bain Birth Biotech for Autoimmune Disorders
BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus erythematosus and plaque psoriasis, and $300 million in funds from Bain Capital.
BMS, Bain Birth Biotech for Autoimmune Disorders Read More »
